United States of America based
BioXcel Therapeutics employs a unique AI platform in an effort to reduce therapeutic development costs and potentially accelerate timelines while aiming to increase the possibility of success.
BXCL501 is an investigational sublingual thin film formulation of dexmedetomidine in development for acute treatment of agitation in multiple neuropsychiatric indications.
BXCL701 is an investigational orally-available systemic innate immunity activator in development for the treatment of a rare form of prostate cancer and for the treatment of pancreatic cancer.
No services posted yet